INC Featured Speakers

INC Featured Speakers
Sunday 28 June, 2020

Michael P. Collins, MD, Medical College of Wisconsin, Milwaukee, WI, USA 
Vasculitic Neuropathies: Updates in Classification, Pathology, and Treatment


Coming Soon


Charlotte Teunissen, PhD  Neurochemistry Lab, Amsterdam University Medical Centers, Amsterdam, Netherlands

Title: Novel Opportunities for Body Fluid Biomarker Development for Neurological Diseases


There is a strong potential in the use of body fluid biomarkers for different clinical purposes in neurological diseases. Such biomarkers can aid in diagnosis, prognosis, patient stratification and treatment effect monitoring. This value of biomarkers is exemplified by current use in diagnosis and follow-up of patients. This does for example include the analysis of cerebrospinal fluid (CSF) in Alzheimer´s disease for tau protein and abeta-peptides, the search for aquaporin autoantibodies in neuromyelitis optica. Rapid technological developments offer opportunities to develop novel and specific body fluid biomarkers, even in blood. This is shown by the use of blood neurofilament light chain in a variety of neurological diseases.

Stephen W. Reddel, PhD University of Sydney, Sydney, Australia  
Beyond Immunoglobulin and Steroids in CIDP: What Can We Learn From Other Diseases?


The established treatment options for CIDP are quite limited, to short term suppressive Ig based therapies (IVIG, SCIG, PLEX) and corticosteroids with their problematic long term side effects. The reasons behind this include disease rarity, heterogeneity, and that it is rarely life-threatening, all of which have contributed to the lack of an evidence base for other longer term and potentially more effective immunotherapies. Nonetheless other treatments often have to be tried in individual CIDP patients, without the trial evidence base. A knowledge base exists in other neurological diseases, including MG, MS and the MOG antibody and NMO variants. This gives some insights into which treatments should be considered and for which subgroups of CIDP, for how long an N=1 treatment trial should continue, and the comparative risks arising.


INC Featured Speakers
Monday 29 June, 2020

Luis Querol, MD, PhD, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain  
Antibodies in Inflammatory Neruopathies: What to Test, How to Test, Why to Test

            Autoantibodies play an important role in the pathogenesis of inflammatory neuropathies. These antibodies are very diverse in their nature, target antigens, testing procedures and clinical implications. Inconsistent results and poor testing standards may then lead to inappropriate conclusions and poor therapeutic choices. The talk will review the different autoantibodies described in the literature focusing in their clinical utility and test caveats and will provide a diagnostic workflow in the detection of autoantibodies in inflammatory neuropathies.

Kazim Sheikh, MBBS, Department of Neurology - McGovern Medical School, Houston, TX, USA
Title: The Role of Fc Receptors in Inflammatory Neuropathy: Emerging Targets for Novel Therapies


Cellular and humoral immune elements are invoked in the pathogenesis of inflammatory neuropathies, such as GBS and CIDP, and current opinion favors the pathogenic role of IgG autoantibodies in these conditions. The talk will review data supporting the critical role of activating FcγRs in experimental models of antibody- and T-cell orchestrated experimental models of inflammatory neuropathies. Modulation of these receptors is a potential treatment approach and a number of FcγR targeting therapies are at various stages of clinical development for such a strategy. Neonatal Fc receptor (FcRn) functions to protect IgG from catabolism and antagonism of this receptor can shorten the half-life of IgGs and IgG autoantibodies. Experimental studies will be reviewed that demonstrate that the FcRn antagonism shortens the half-life of circulating pathogenic anti-neural autoantibodies, which can reduce Ab-mediated nerve injury. In this context, FcRn inhibitors are at advanced stages of clinical development for various indications including CIDP.



Thank you to our 2019 PNS Sponsors!